PDSS2: A Potential Drug Target for Perinod Sarcoma (G57107)

Target Name: PDSS2

NCBI ID: G57107

PDSS2

PDSS2: A Potential Drug Target for Perinod Sarcoma

PDSS2 (Perinod sarcoma-associated protein 2) is a protein that is expressed in a variety of tissues, including the skin, hair, and nervous system. It is also known as C6orf210, and it has been identified as a potential drug target or biomarker for the treatment of perinod sarcoma, a type of cancer that affects the skin.

PDSS2 is a transmembrane protein that is characterized by its extracellular domain, which is composed of a catalytic center and a transmembrane region. The catalytic center contains a zinc ion, which is known to play a role in the regulation of various cellular processes. The transmembrane region contains several potential binding sites, including a interaction with the protein PDGF-BB.

Perinod sarcoma is a type of cancer that arises from the skin, and it is characterized by the rapid growth of a new tissue, called a sarcoma. This type of cancer is often treated with chemotherapy, which involves the use of drugs to kill the cancer cells. However, the treatment of perinod sarcoma can be challenging, as the cancer cells can often become resistant to the drugs that are used to treat it.

PDSS2 has been identified as a potential drug target or biomarker for the treatment of perinod sarcoma because it is involved in the regulation of the cell cycle and has been shown to be expressed in the cells that are affected by perinod sarcoma. Additionally, PDSS2 has been shown to interact with the protein PDGF-BB, which is a key regulator of the cell cycle and has been shown to play a role in the development and progression of perinod sarcoma.

In conclusion, PDSS2 is a protein that has been identified as a potential drug target or biomarker for the treatment of perinod sarcoma. Further research is needed to determine the exact role of PDSS2 in this disease and to develop effective treatments.

Protein Name: Decaprenyl Diphosphate Synthase Subunit 2

Functions: Heterotetrameric enzyme that catalyzes the condensation of farnesyl diphosphate (FPP), which acts as a primer, and isopentenyl diphosphate (IPP) to produce prenyl diphosphates of varying chain lengths and participates in the determination of the side chain of ubiquinone (PubMed:16262699). Supplies nona and decaprenyl diphosphate, the precursors for the side chain of the isoprenoid quinones ubiquinone-9 (Q9) and ubiquinone-10 (Q10) respectively (PubMed:16262699). The enzyme adds isopentenyl diphosphate molecules sequentially to farnesyl diphosphate with trans stereochemistry (PubMed:16262699). May play a role during cerebellar development (By similarity). May regulate mitochondrial respiratory chain function (By similarity)

The "PDSS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDSS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets